← back to search

Rick Kapur

Sanquin · NL
Area of research
Hematology · Biochemistry
Research interest
Research interests include Platelet Disorders and Treatments, Blood groups and transfusion, Blood transfusion and management, and Heparin-Induced Thrombocytopenia and Thrombosis.
h-index
34
citations
4,256
works
171
NIH funding
primary concept
Medicine
email

Recent publications

Plasmin tames lung inflammation by redirecting immune cells.
2026cited by 0position: contributordoi
Neutrophil-reactive autoantibodies in blood donors: Can we expect TRALI?
2026cited by 0position: contributordoi
Antibody-mediated multicellular pathophysiology of heparin-induced thrombocytopenia and vaccine-induced thrombotic thrombocytopenia: the dynamic roles of platelets, neutrophils, endothelial cells, and monocytes.
2026cited by 0position: contributordoi
MicroRNAs as potential architects of immune dysregulation and megakaryocytic failure in immune thrombocytopenia.
2026cited by 0position: contributordoi
Anti-HPA-1a Fetal-Neonatal AlloImmune Thrombocytopenia: Reframing Diagnostics, Pathophysiology, and Management.
2026cited by 0position: contributordoi
Longitudinal plasma proteomics in romiplostim-treated patients with immune thrombocytopenia.
2026cited by 0position: contributordoi
Key features of the underlying pathophysiology of Transfusion-related acute lung injury.
2025cited by 4position: contributordoi
The ‘Stop TPO‐RA in ITP Patients’ study: Clinical and immune modulatory effects of romiplostim tapering
British Journal of Haematology 2025cited by 4position: contributordoi
The intestinal flora: The key to unraveling heterogeneity in immune thrombocytopenia?
2025cited by 2position: contributordoi
HPA-1a antibodies in FNAIT do not distinguish αvβ3 from αIIbβ3, and bind inactive integrins more strongly than active integrins.
2025cited by 2position: contributordoi
Inhibition of terminal complement complex formation alleviates murine antibody-mediated TRALI.
2025cited by 2position: contributordoi
Platelet transfusion induces transfusion-associated circulatory overload in rats with myocardial infarction.
2025cited by 1position: contributordoi
Transfusion-related acute lung injury: experimental models to study pathogenesis and therapeutic strategies.
2025cited by 0position: contributordoi
Platelets and monocytes: A dynamic duo aiding in the prediction of the clinical response to thrombopoietin receptor agonists in immune thrombocytopenia?
2025cited by 0position: contributordoi
Feasibility of plasma proteomics in patients with immune thrombocytopenia.
2025cited by 0position: contributordoi
Platelet sequestration patterns and clearance rates in healthy individuals.
2025cited by 0position: contributordoi
Increased effector memory CD4<sup>+</sup> T cells are associated with chronic childhood immune thrombocytopenia.
2025cited by 0position: contributordoi
PF4-dependent P-selectin expression assay in comparison to the heparin-induced platelet activation assay for the diagnosis of heparin-induced thrombocytopenia.
2025cited by 0position: contributordoi
Complement activation drives antibody-mediated transfusion-related acute lung injury via macrophage trafficking and formation of NETs.
2024cited by 28position: contributordoi
Characterization of reverse-engineered anti-PF4 stereotypic antibodies derived from serum of patients with VITT.
2024cited by 10position: contributordoi
Platelet TGF-β triggers immunosuppression in ITP.
2024cited by 3position: contributordoi
Broadening the horizon of immune thrombocytopenia through Omics approaches.
2024cited by 2position: contributordoi
Laboratory approach for vaccine-induced thrombotic thrombocytopenia diagnosis in the Netherlands.
2024cited by 2position: contributordoi
Does anti-HPA-1a affect birthweight in fetal and neonatal alloimmune thrombocytopenia?
2024cited by 2position: contributordoi
Developments in Transfusion Medicine: Pulmonary Transfusion Reactions and Novel Blood Cell Labeling Techniques.
2024cited by 1position: contributordoi
The importance of disrupting complement activation in acute lung injury.
2024cited by 1position: contributordoi
Antibodies against Platelet Glycoproteins in Clinically Suspected VITT Patients.
2024cited by 1position: contributordoi
Let's YAP about ITP.
2024cited by 0position: contributordoi
Fetal and neonatal alloimmune thrombocytopenia: Current pathophysiological insights and perspectives for future diagnostics and treatment.
2023cited by 16position: contributordoi
Mechanism and intervention of murine transfusion-related acute lung injury caused by anti-CD36 antibodies
JCI Insight 2023cited by 14position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 27 papers (2019–2026)John W. Semple · University of Toronto19 papers (2016–2026)Gestur Vidarsson · Amsterdam University Medical Centers14 papers (2020–2025) · 14 papers (2019–2026)Jaap Jan Zwaginga · Sanquin4 papers (2020–2024)Matthew T. Rondina · University of Utah4 papers (2016–2018)C. Ellen van der Schoot · Amsterdam University of Applied Sciences3 papers (2022–2024)Alexander P. J. Vlaar · Amsterdam University Medical Centers3 papers (2019–2025)Leendert Porcelijn · Sanquin3 papers (2022–2025)Manfred Wuhrer · Netherlands Metabolomics Centre3 papers (2020–2022)Masja de Haas · 3 papers (2022–2025) · 3 papers (2022–2024)Anne Zufferey · Centre hospitalier de l'Université Laval3 papers (2017–2021) · 3 papers (2016–2017)Éric Boilard · Centre hospitalier universitaire de Québec2 papers (2021–2021)James B. Bussel · Cornell University2 papers (2024–2026)Sylvain Bourgoin · Centre hospitalier universitaire de Québec2 papers (2021–2021)David E. Schmidt · Karolinska Institutet2 papers (2020–2021)Xiuzhang Xu · Key Laboratory of Guangdong Province2 papers (2023–2025) · 2 papers (2024–2026)